McKesson Corporation's Stock Analysis

McKesson Updates Fiscal 2026 Guidance and Long-Term Financial Targets

On September 23, 2025, McKesson Corporation hosted its Investor Day, where it provided updates on its Fiscal 2026 guidance and long-term financial targets. The company raised its Adjusted Earnings per Diluted Share guidance for Fiscal 2026 to a range of $38.05 to $38.55, up from the previous range of $37.10 to $37.90. Additionally, McKesson introduced a new organizational structure aimed at enhancing growth and shareholder value, while reaffirming its commitment to its strategic priorities in North American pharmaceutical distribution and expanding services in oncology and biopharma.

McKesson also updated its long-term growth targets, increasing the projected growth rate for Adjusted Earnings per Diluted Share from 12%-14% to 13%-16%. The company emphasized its focus on portfolio optimization and strategic growth objectives, which are expected to drive sustainable growth and improve health outcomes. Upcoming investor events include the release of second quarter fiscal 2026 financial results on November 5, 2025, and participation in several healthcare conferences through early 2026.

Sep 23, 2025 08:03:51

McKesson Announces New Segment Reporting Structure for Investors

McKesson Corporation will begin reporting its financial results across four new segments starting in the second quarter of fiscal 2026: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. This reorganization aims to better reflect how the company's Chief Executive Officer allocates resources and assesses performance. The previous financial statements remain unaffected by these changes, which also include the company's Norwegian operations under a new category labeled 'Other.'

Additionally, McKesson is providing supplemental historical financial information in accordance with the new segments for fiscal years 2024 and 2025. This information is intended to assist investors in understanding the impact of the segment changes on the company's financial performance. The company will also present Non-GAAP financial measures, which exclude certain expenses and adjustments, to provide a clearer picture of its operating results and facilitate comparison with other companies in the industry.

Sep 18, 2025 08:00:41

McKesson Reports Q1 Results and Raises EPS Guidance

McKesson Corporation reported consolidated revenues of $97.8 billion for the first quarter ended June 30, 2025, reflecting a 23% increase compared to the previous year. Earnings per diluted share decreased to $6.25, down $0.75 from the prior year, primarily due to a higher provision for bad debts related to the Rite Aid bankruptcy. However, adjusted earnings per diluted share rose by 5% to $8.26, driven by operational growth across the business. The company also announced the completion of acquisitions for controlling interests in PRISM Vision Holdings and Core Ventures, contributing to its expansion in oncology and specialty solutions.

Additionally, McKesson's Board of Directors approved a 15% increase in the quarterly dividend to $0.82 per share, marking the ninth consecutive year of dividend increases. The company raised its fiscal 2026 adjusted earnings per diluted share guidance to a range of $37.10 to $37.90, indicating expected growth of 12% to 15% from the prior year. For the first quarter, McKesson returned $671 million to shareholders, including stock repurchases and dividend payments, while reporting negative free cash flow of $1.1 billion due to cash used for operations and acquisitions.

Aug 06, 2025 16:06:31

McKesson Annual Meeting Vote Results for Shareholders

McKesson Corporation held its Annual Meeting of Shareholders on July 30, 2025. During the meeting, all nominated individuals proposed by the Board of Directors were elected to serve as directors, receiving the necessary votes for approval.

Additionally, shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. An advisory proposal regarding the compensation of the Company’s named executive officers was also approved by the shareholders.

Aug 01, 2025 08:54:21

McKesson Corporation Announces Offering of $2 Billion in Notes

McKesson Corporation plans to issue $650 million in 4.650% Notes due 2030, $650 million in 4.950% Notes due 2032, and $700 million in 5.250% Notes due 2035, totaling $2 billion. The underwriting will be managed by Barclays Capital Inc., BofA Securities, Deutsche Bank Securities Inc., and J.P. Morgan Securities LLC. The Notes will be issued under an indenture with U.S. Bank Trust Company as trustee and will be available in book-entry form through The Depository Trust Company.

The company has confirmed compliance with registration requirements under the Securities Act, with the registration statement having become effective. McKesson Corporation represents that there have been no material adverse changes in its financial condition since the last reported period. Deloitte & Touche LLP serves as the independent registered public accounting firm for the company, ensuring that the financial statements presented comply with the necessary accounting standards.

May 30, 2025 10:15:08

McKesson Reports Q4 and FY2025 Results; Plans Segment Separation

McKesson Corporation announced its fourth quarter and full year results for fiscal 2025, reporting consolidated revenues of $90.8 billion for Q4, a 19% increase year-over-year, and full year revenues of $359.1 billion, up 16%. The company also reported earnings per diluted share of $10.01 for Q4, an increase of $3.99, and $25.72 for the full year, up $3.33. Adjusted earnings per diluted share for Q4 were $10.12, reflecting a 64% increase, driven by strong operational growth and a lower tax rate. For fiscal 2026, McKesson established an adjusted earnings per diluted share guidance range of $36.75 to $37.55, indicating projected growth of 11% to 14% compared to the prior year. Additionally, the company reaffirmed its long-term adjusted earnings growth target of 12% to 14% and updated its U.S. Pharmaceutical segment operating profit growth target to 6% to 8% from 5% to 7%.

In a strategic move, McKesson announced its intention to separate its Medical-Surgical Solutions segment into an independent company. The separation aims to enhance operational focus and unlock value for shareholders, allowing both McKesson and the new entity to pursue their respective growth strategies more effectively. This decision is part of McKesson's disciplined portfolio management approach and is expected to lead to two well-capitalized companies capable of maximizing growth and operational excellence in their markets. Further details on the timing and form of the separation will be provided as the process progresses.

May 08, 2025 16:06:16

McKesson Reports $95.3 Billion Revenue and Adjusted EPS Increase

McKesson Corporation reported a revenue increase of 18%, reaching $95.3 billion for the third quarter, driven by growth in its U.S. Pharmaceutical segment. The earnings per diluted share rose significantly to $6.95, an increase of $2.53 compared to the previous year. The company also raised its full-year adjusted earnings guidance to a range of $32.55 to $32.95, reflecting a growth of 19% to 20% compared to the prior year. Additionally, McKesson announced its intention to acquire a controlling interest in PRISM Vision Holdings, LLC, which is expected to enhance its offerings in community practice management and specialty solutions. The company also returned $3.1 billion to shareholders through stock repurchases and dividends during the first nine months of the fiscal year.

On the downside, net income attributable to McKesson Corporation decreased by 8% year-to-date, totaling $2.035 billion. The Medical-Surgical Solutions segment faced a revenue decline of 3%, attributed to lower contributions from illness season vaccines and testing in the primary care channel. Adjusted earnings per diluted share saw a modest increase of 4% to $8.03, but this was partially offset by a higher tax rate. Furthermore, McKesson reported negative free cash flow of $2.2 billion, indicating challenges in cash generation despite robust operational performance.

Feb 05, 2025 16:05:22

McKesson Reports $93.7 Billion Revenue in Q2 Fiscal 2025

McKesson Corporation announced a significant increase in consolidated revenues, reaching $93.7 billion for the second quarter, which is a 21% rise compared to the same period last year. The company also reported a 13% increase in adjusted earnings per diluted share, amounting to $7.07, supported by growth in its U.S. Pharmaceutical segment and a reduction in the number of shares outstanding. Additionally, McKesson is raising its full-year adjusted earnings guidance, reflecting confidence in its ongoing operations and strategic initiatives, including the acquisition of Florida Cancer Specialists.

However, the company faced notable challenges, with earnings per diluted share dropping to $1.87, a decrease of $3.05 from the previous year, primarily due to significant charges related to the sale of its Canadian retail businesses and restructuring efforts. Net income attributable to McKesson Corporation also fell by 64%, highlighting the impact of these financial adjustments. Furthermore, while the U.S. Pharmaceutical segment saw revenue growth, the overall operating income declined by 39%, indicating pressures on profitability despite higher sales.

Nov 06, 2024 16:05:21

McKesson Corporation Announces $500 Million Notes Offering

McKesson Corporation is set to issue $500 million in 4.250% Notes due in 2029, with Citigroup, HSBC, and U.S. Bancorp acting as underwriters. The company has confirmed compliance with regulatory requirements and maintains a strong financial position, indicating that it has not faced any material adverse changes recently, which is a positive sign for investors.

However, there are several technical aspects related to the offering that may concern some stakeholders, such as the complexities surrounding the registration statement and the compliance with various securities regulations. While the company presents a solid financial picture, the intricate details of the offering process could pose challenges in communication and understanding for potential investors.

Sep 10, 2024 16:11:17

McKesson Acquires Controlling Interest in Florida Cancer Specialists

McKesson Corporation has announced a significant agreement to acquire a controlling interest in Core Ventures, a subsidiary of the Florida Cancer Specialists & Research Institute, for approximately $2.49 billion. This acquisition will enhance McKesson’s oncology platform and integrate Florida Cancer Specialists into The US Oncology Network, which aims to improve access to quality cancer care. The partnership is expected to bring advanced treatments and better patient experiences while maintaining the independent ownership of Florida Cancer Specialists, which has a long history of providing care to cancer patients across Florida.

The acquisition is seen as a strategic move to bolster community-based oncology care, with both McKesson and Florida Cancer Specialists expressing optimism about the benefits for patients. Leaders from both organizations highlighted their shared commitment to improving patient outcomes and making high-quality care more accessible. However, the transaction is still subject to regulatory approvals, and there are inherent uncertainties associated with such large acquisitions, which could impact the anticipated benefits.

Aug 26, 2024 08:04:26